Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

Merck has partnered with Hansoh, a Chinese biopharmaceutical company, for a global licensing deal to develop an oral GLP-1 ...

Signs at AMPAC Fine Chemicals' location in the Petersburg Industrial Park have already been changed to 'Novo Nordisk' in advance of the acquisition ...

Four months ago, a New Jersey judge rejected the case, with Novo saying it would appeal. In early 2023, shortly after Eli Lilly slashed the price of its insulin in the U.S. by 70%, Novo Nordisk ...

Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on ...

The state's fastest-growing such health care facility will debut 30,000 square feet of brand-new space to serve community ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion ... Catalent offloads New Jersey manufacturing plant, HQ to Belgian CDMO Ardena Elsewhere, consumer groups and lawmakers ...

A lawyer for the employers predicts that discovery will show that collusion between drugmakers and PBMs had a significant ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...